Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Blood (2019) 134 (Supplement_1): 5098.

https://doi.org/10.1182/blood-2019-128583

Published: 2019

Journal Articles

An IDO1 -Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

Simone Ragaini, MD, Sarah Wagner, BSc MSc, Giovanni Marconi, Sarah Parisi, MD PhD, Chiara Sartor, MD, Jacopo Nanni, MD, Gianluca Cristiano, Annalisa Talami, MD, Matteo Olivi, MD, Darina Ocadlikova, PhD, Marilena Ciciarello, PhD, Giulia Corradi, PhD, Emanuela Ottaviani, Cristina Papayannidis, Stefania Paolini, MD PhD, Jayakumar Vadakekolathu, PhD, Michele Cavo, Sergio Rutella, MD PhD FRCPath, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 5193.

https://doi.org/10.1182/blood-2019-128348

Published: 2019

Journal Articles

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Giovanni Marconi, Roberta di Nicola, Chiara Sartor, MD, Mariachiara Abbenante, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Sarah Parisi, MD PhD, Carmen Baldazzi, PhD, Maria Chiara Fontana, PhD, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli, MD, Michele Baccarani, MD, Cristina Papayannidis, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2617.

https://doi.org/10.1182/blood-2019-130630

Published: 2019

Journal Articles

Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

Giovanni Marconi, Federico Ravaioli, MD, Giovanni Martinelli, MD, Elton Dajti, Maria Chiara Abbenante, MD, Chiara Sartor, MD, Luigina Vanessa Alemanni, MD, Jacopo Nanni, MD, Sarah Parisi, MD PhD, Giovanni Marasco, MD, Gianluca Cristiano, MD, Amanda Vestito, MD, Francesca Bonifazi, Stefania Paolini, MD PhD, Antonio Curti, MD PhD, Davide Festi, MD, Michele Cavo, Cristina Papayannidis, Antonio Colecchia, MD

Blood (2019) 134 (Supplement_1): 1343.

https://doi.org/10.1182/blood-2019-130632

Published: 2019

Journal Articles

MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration

Giovanni Marconi, MD, Maria Chiara Fontana, MSc, Eugenio Fonzi, PhD, Cristina Papayannidis, MD, Mariachiara Abbenante, MD, Emanuela Ottaviani, Nicoletta Testoni, BSc, Giorgia Simonetti, PhD, Antonella Padella, Chiara Sartor, Carmen Baldazzi, Jacopo Nanni, MD, Luca Bertamini, MD, Andrea Ghelli Luserna Di Rora, Valentina Robustelli, Martina Pazzaglia, Elena Tenti, PhD, Sarah Parisi, MD PhD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 3958.

https://doi.org/10.1182/blood.V130.Suppl_1.3958.3958

Published: 2017

Journal Articles

Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization

Blood (2017) 130 (Supplement 1): 2720.

https://doi.org/10.1182/blood.V130.Suppl_1.2720.2720

Published: 2017

Journal Articles

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Y Follo, PhD, Andrea Pellagatti, PhD, Richard N Armstrong, PhD, Stefano Ratti, MD, Sara Mongiorgi, PhD, Annalisa Astolfi, PhD, Valentina Indio, PhD, Cristina Clissa, MD PhD, Domenico Russo, MD, Marco Gobbi, MD, Marilena Barraco, PhD, Sarah Parisi, MD PhD, Andrea Pession, MD, Michele Cavo, MD, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, PhD, Carlo Finelli, MD

Blood (2017) 130 (Supplement 1): 5299.

https://doi.org/10.1182/blood.V130.Suppl_1.5299.5299

Published: 2017

Journal Articles

A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination

Jacopo Nanni, MD, Giorgia Simonetti, PhD, Giovanni Marconi, MD, Maria Chiara Fontana, MSc, Samantha Bruno, MSc, Cristina Papayannidis, MD, Antonella Padella, Mariachiara Abbenante, MD, Silvia lo Monaco, Elena Tenti, PhD, Chiara Sartor, Sarah Parisi, MD PhD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 4969.

https://doi.org/10.1182/blood.V130.Suppl_1.4969.4969

Published: 2017

Journal Articles

Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations

Blood (2016) 128 (22): 1678.

https://doi.org/10.1182/blood.V128.22.1678.1678

Published: 2016

Journal Articles

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1679.

https://doi.org/10.1182/blood.V128.22.1679.1679

Published: 2016

Journal Articles

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Annalisa Astolfi, PhD, Domenico Russo, MD, Marco Gobbi, MD, Costanza Bosi, MD, Monica Crugnola, MD, Marta Stanzani, MD, Stefano Ratti, MD, Sarah Parisi, MD, Marilena Barraco, PhD, Lucia Manzoli, MD, Andrea Pession, MD, Lucio Cocco, MD, PhD, Carlo Finelli, MD

Blood (2016) 128 (22): 5091.

https://doi.org/10.1182/blood.V128.22.5091.5091

Published: 2016

Journal Articles

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

Blood (2016) 128 (22): 5191.

https://doi.org/10.1182/blood.V128.22.5191.5191

Published: 2016

Journal Articles

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2016) 128 (22): 3169.

https://doi.org/10.1182/blood.V128.22.3169.3169

Published: 2016

Journal Articles

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2015) 126 (23): 2513.

https://doi.org/10.1182/blood.V126.23.2513.2513

Published: 2015

Journal Articles

Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients

Blood (2015) 126 (23): 3198.

https://doi.org/10.1182/blood.V126.23.3198.3198

Published: 2015

Journal Articles

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Blood (2015) 126 (23): 2871.

https://doi.org/10.1182/blood.V126.23.2871.2871

Published: 2015

NARROW

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

An IDO1 -Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration

Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination

Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only